Contemporary Pediatrics, Digital Edition, April 2012

Food Insecurity and the Dangers of Infant Formula Dilution

Even low-level lead exposure in early childhood may speed up memory loss, according to a new study using a cognitive task to measure forgetting rates.

January 30th 2023

An 11-year-old boy with a petechial rash: A peculiar presentation

Drashti Patel, BS, BA;Jyoti Budania, MD

Demystifying Infant Formula

His vital signs in clinic were within normal limits, and the only additional finding at this time was a nontender, nonpruritic, and nonpalpable petechial rash on the bilateral lower extremities.

October 11th 2022

Specific groups with chronic conditions who could most benefit from RSV prophylaxis

Joshua Fitch, Senior Editor

FDA accepts NDA for ET-600, desmopressin oral solution for pediatric AVP deficiency

A newly-published study identified specific groups of higher-risk children that could benefit most from monoclonal antibodies.

Lead exposure in early childhood linked to faster memory loss

The FDA accepted Eton Pharmaceuticals' NDA for ET-600 for pediatric arginine vasopressin deficiency, with a target action date in February of 2026.

Related Content

Food Insecurity and the Dangers of Infant Formula Dilution

Even low-level lead exposure in early childhood may speed up memory loss, according to a new study using a cognitive task to measure forgetting rates.

January 30th 2023

An 11-year-old boy with a petechial rash: A peculiar presentation

Drashti Patel, BS, BA;Jyoti Budania, MD

Demystifying Infant Formula

His vital signs in clinic were within normal limits, and the only additional finding at this time was a nontender, nonpruritic, and nonpalpable petechial rash on the bilateral lower extremities.

October 11th 2022

Specific groups with chronic conditions who could most benefit from RSV prophylaxis

Joshua Fitch, Senior Editor

FDA accepts NDA for ET-600, desmopressin oral solution for pediatric AVP deficiency

A newly-published study identified specific groups of higher-risk children that could benefit most from monoclonal antibodies.